Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0050)
Name
Pyridoxine
Synonyms
pyridoxine; 65-23-6; vitamin B6; Pyridoxol; Pyridoxin; Gravidox; 3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine; Adermine; Hydoxin; Pyridoxolum; 3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-; 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol; 5-Hydroxy-6-methyl-3,4-pyridinedimethanol; Pyridoxinum; Piridossina; Piridoxina; Piridossina [DCIT]; 3-Hydroxy-4,5-dimethylol-alpha-picoline; Pyridoxinum [INN-Latin]; Piridoxina [INN-Spanish]; Hexabione; (5-Hydroxy-6-methylpyridine-3,4-diyl)dimethanol; 12001-77-3; 2-Picoline-4,5-dimethanol, 3-hydroxy-; Pyridoxine [INN:BAN]; 2-Methyl-3-hydroxy-4,5-di(hydroxymethyl)pyridine; Vitamin V6; 2-Methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine; 2-Methyl-4,5-bis(hydroxymethyl)-3-hydroxypyridine; CHEBI:16709; Aderoxine; Hexa-Betalin; EINECS 200-603-0; 4,5-bis(hydroxymethyl)-2-methyl-pyridin-3-ol; UNII-KV2JZ1BI6Z; KV2JZ1BI6Z; VitaminB6; Pyridoxin hydrochloride; vitamin B-6; 2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine; Adermin hydrochloride; NSC-759148; DTXSID4023541; Pyridoxine free base; 2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin [German]; 4,5-Bis(hydroxymethyl)-2-methyl-3-pyridinol; Prestwick0_000623; Prestwick1_000623; Prestwick2_000623; Prestwick3_000623; 2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin; TimTec1_000657; Oprea1_061614; BSPBio_000586; CBDivE_015627; SPBio_002805; DTXCID903541; BPBio1_000646; Pyridoxine hydrogen chloride; Pyridoxine (INN); M.V.I.-12; STK177324; 65-23-6 (FREE BASE); 2-methyl-3-hydroxy-4,5-bis(hydroxy-methyl) pyridine; 3-hydroxy-2-Picoline-4,5-dimethanol; NSC 759148; DB00165; CAS-58-56-0; SMP2_000230; NCGC00016261-01; NCGC00016261-03; PYRIDOXINE [INN]; C00314; Tex Six T.R.; AC-907/25014218; PN; Adermin; Bezatin; Pirivitol; CAS-65-23-6; NSC36225; Pyridoxine (Vit B6); SR-05000001644; NCGC00164317-01; pyridoxina; Hexermine; Nestrex; Pridoxine; vitaminum b6; Rodex TD; Beesix (Salt/Mix); nchembio.93-comp1; Becilan (Salt/Mix); Benadon (Salt/Mix); Hexobion (Salt/Mix); Vitamin B6 (TN); Pyridoxol; Vitamin B6; Pyridoxine, >=98%; Hexabetalin (Salt/Mix); PYRIDOXINE [MI]; Vitamin b6,hydrochloride; LS-134393; PYRIDOXINE [INCI]; PYRIDOXINE [VANDF]; bmse000288; SCHEMBL3506; CHEMBL1364; PYRIDOXINE [WHO-DD]; BIDD:PXR0180; VITAMIN B6 [VANDF]; P5669_SIGMA; PYRIDOXINE [ORANGE BOOK]; A11HA02; NSC36225 (HCL); Pyridoxol, Vitamin B6, Gravidox; AIDS006784; HMS2093L07; KUC106691N; Pharmakon1600-01505453; AIDS-006784; BCP27975; HY-B1328; Tox21_113644; Tox21_300365; BBL005552; BDBM50103505; c1302; MFCD00006335; NSC759148; s3980; ZINC00049154; AKOS005410791; Tox21_113644_1; CCG-213453; CS-W019950; 2-methyl-4,5-dimethylol-pyridin-3-ol; Vitamin B6 100 microg/mL in Methanol; NCGC00016261-02; NCGC00016261-04; NCGC00016261-05; NCGC00016261-08; NCGC00164317-02; NCGC00254340-01; AC-14512; DS-11013; 58-56-0 (HCL); KSC-11-207-23; SBI-0206844.P001; 3-Hydroxy-4,5-dimethylol-.alpha.-picoline; AM20070169; FT-0631288; FT-0674200; EN300-39851; 4,5-bis(hydroxymethyl)-2-methylpyridine-3-ol; D08454; O10129; 4,5-Bis(hydroxymethyl)-2-methyl-3-pyridinol #; A835033; Q423746; Q-201646; SR-05000001644-1; SR-05000001644-3; 2B3E07D2-E4CC-4CC5-B085-6070BA01F9F0; Z382721012; 2-methyl-3-hydroxy-4-hydroxymethyl-5-hydroxymethyl pyridine; InChI=1/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H

    Click to Show/Hide
Status
Approved
Drug Type
Small molecular drug
Structure
Formula
C8H11NO3
IUPAC Name
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol
Canonical SMILES
CC1=NC=C(C(=C1O)CO)CO
InChI
InChI=1S/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H3
InChIKey
LXNHXLLTXMVWPM-UHFFFAOYSA-N
PubChem CID
1054
TTD Drug ID
D07MUN
Full List of Ferroptosis Target Related to This Drug
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Myocardial injury ICD-11: NB31
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell proliferation
Cell apoptosis
In Vitro Model CHO-S/H9C2 cells Normal Cricetulus griseus CVCL_A0TS
In Vivo Model
Male c57BL/6 mice (8 weeks old) were purchased from Beijing Wei Tong Li Hua Experimental Animal Technology Co. Ltd. (Beijing, China). Mice were divided into control (n = 8), LPS (n = 9), and VitB6+LPS (n = 9) groups. Mice were pretreated with PBS or VitB6 for 6 h and then treated with LPS (4 mg/kg) for 24 h. Cardiac ultrasound was performed before sacrifice. Inhaled isoflurane was given to mice for volatile anesthesia and the chest hair was removed with a depilatory cream. Then, mice were fixed on the warmed imaging platform and wore with the coupling agent. The Vevo2100 imaging system, equipped with a 40-MHz high-frequency transducer (VisualSonics Inc., Toronto, Canada), was applied to perform non-invasive examinations. The M-mode echocardiogram at the parasternal long axis was used to obtain the ejection fraction (EF) of left ventricular and fractional shortening (FS).

    Click to Show/Hide
Response regulation Vitamin B6 (VitB6) is a water-soluble vitamin and includes pyridoxine, pyridoxal, pyridoxamine, and their phosphorylated forms. VitB6 regulated the expression of LPS-induced apoptosis-related proteins and iron regulatory proteins. It mediated the expression of Nrf2, transcription factor NF-E2-related factor 2, which promoted the expression of antioxidant enzymes and restrained LPS-induced ferroptosis and apoptosis. Overall, VitB6 can be used on novel therapies to relieve LPS-induced myocardial injury.
References
Ref 1 Vitamin B6 Alleviates Lipopolysaccharide-induced Myocardial Injury by Ferroptosis and Apoptosis Regulation. Front Pharmacol. 2021 Dec 24;12:766820. doi: 10.3389/fphar.2021.766820. eCollection 2021.